0000000001040560

AUTHOR

Götz M. Richter

showing 2 related works from this author

Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions : results of a mu…

2008

The purpose of this phase III clinical trial was to compare two different extracellular contrast agents, 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine, for magnetic resonance imaging (MRI) in patients with known or suspected focal renal lesions. Using a multicenter, single-blind, interindividual, randomized study design, both contrast agents were compared in a total of 471 patients regarding their diagnostic accuracy, sensitivity, and specificity to correctly classify focal lesions of the kidney. To test for noninferiority the diagnostic accuracy rates for both contrast agents were compared with CT results based on a blinded reading. The average diagnostic accuracy across the three bli…

Gadobutrol; Gadopentate dimeglumine; Renal lesions; MRI; Diagnostic differentiation; NoninferiorityGadolinium DTPAMalemedicine.medical_specialtyContrast MediaRenal lesionsSensitivity and SpecificityGadobutrollaw.inventionGadobutrolPrecontrastRandomized controlled trialmagnetic resonance contrast medialawmedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingSingle-Blind Methodddc:610Neuroradiologymedicine.diagnostic_testbusiness.industryDiagnostic differentiationUltrasoundReproducibility of ResultsMagnetic resonance imagingInterventional radiologyGeneral MedicineNoninferiorityMiddle AgedImage EnhancementMagnetic Resonance ImagingKidney NeoplasmsClinical trialEuropeRadiology Nuclear Medicine and imagingFemaleGadopentate dimeglumineRadiologybusinessNuclear medicinemedicine.drugMRI
researchProduct

Therapeutische Alternativen beim fortgeschrittenen Nierentumor

1988

Metastasierte Nieren-Carcinome stellen ein ungelostes therapeutisches Problem dar. Seit uber 20 Jahren werden in die Immuntherapie immer wieder Erwartungen gesetzt, die sich letztlich nicht erfullt haben. Die Liste immunologischer Therapieansatze ist lang und reicht von der BCG-Therapie bis zu den verschiedenen Interferonen. Damit konnten zwar in wenigen Fallen komplette Metastasenregressionen erzielt werden. Ein therapeutischer Durchbruch war es jedoch nicht.

researchProduct